In that regard, we have discussed how other signaling pathways impinge on the PI3K/Akt/mTOR signaling pathway activity and provided rationale for combining PI3K/Akt/mTOR inhibitors with novel targeted agents that have emerged as potential therapeutic candidates for AML. The gene discussed is PIK3CD; the disease is acute myeloid leukemia.